AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

The Lundquist Institute Promotes Jody Spillane to Senior Vice President of Public Affairs

December 19, 2019 GMT
The Lundquist Institute Promotes Jody Spillane to Senior Vice President of Public Affairs
The Lundquist Institute Promotes Jody Spillane to Senior Vice President of Public Affairs

LOS ANGELES--(BUSINESS WIRE)--Dec 19, 2019--

The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Jody Spillane to Senior Vice President of Public Affairs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005210/en/

The Lundquist Institute Promotes Jody Spillane to Senior Vice President of Public Affairs (Photo: Business Wire)

In her new and expanded role, Spillane will oversee the institute’s communications strategy in addition to assisting in government relations efforts and leading the organization’s education and training efforts. In her new role she will work closely with community stakeholders, public officials and the news media to advance The Lundquist Institute’s mission. Spillane is particularly passionate about issues affecting women and children, and intends to use her position to support The Lundquist Institute’s work in that area.

Previously, as Vice President for Education and Executive Communications at the Lundquist Institute, Spillane was instrumental in launching the institute’s first doctoral program in translational biomedical research, the first comprehensive degree of its kind.

Spillane brings with her more than 30 years of management experience in education and training, outreach and communications. Prior to her work with The Lundquist Institute, she participated in the launch and was Program Administrator for UCLA ACCESS, an umbrella program which became a national model for admissions and training for graduate students entering Ph.D. programs. While there she worked closely with The Lundquist Institute’s current President and CEO David Meyer, PhD.

“I have worked alongside Jody for several years and am thrilled that she will have an even bigger role as The Lundquist Institute enters a transformative phase,” said Meyer. “She is the right person to help The Lundquist Institute achieve the recognition it deserves for decades of life-saving innovations.”

“I am very excited about the potential for expanded impact that this new role affords on behalf of The Lundquist Institute,” said Spillane. “It is an absolute privilege to work with the organization’s fellow leaders and our stellar investigators who continually strive to advance research and innovation, saving lives throughout the world. I am honored to be in a position to help raise awareness for the incredible work and contributions our investigators make worldwide.”

Spillane’s promotion comes as The Lundquist Institute enters a new era following its recent name change, which followed a $70 million gift from philanthropists Melanie and Richard Lundquist. The institute also opened a $63-million, four-story, 78,000 square-foot research building earlier this year that is equipped with some of the most advanced life sciences technology and contains an 18,000 square foot incubator, “BioLabs LA at The Lundquist.”

About The Lundquist Institute: Research with reach

The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, The Lundquist Institute is poised to serve as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous orphan diseases, and is responsible for three FDA-approved drugs including the first approved treatment for sickle cell disease in 20 years. Find out more at https://lundquist.org.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191219005210/en/

CONTACT: Kevin Byrum

kbyrum@vectisstrategies.com

310-414-9040 x114

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE RESEARCH SEARCH ENGINE OPTIMIZATION PUBLISHING GENERAL HEALTH HEALTH COMMUNICATIONS

SOURCE: The Lundquist Institute

Copyright Business Wire 2019.

PUB: 12/19/2019 10:13 AM/DISC: 12/19/2019 10:13 AM

http://www.businesswire.com/news/home/20191219005210/en